Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia
This study is currently recruiting participants.
Verified December 2012 by Stanford University
Sponsor:
Stanford University
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01108497
First received: April 20, 2010
Last updated: December 11, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
We will study gene and protein expression in leukemia cells of children diagnosed with acute leukemia. We hope to identify genes or proteins which can help us grade leukemia at diagnosis in order to: (a) develop better means of diagnosis and (b) more accurately choose the best therapy for each patient.
| Condition | Intervention |
|---|---|
|
Leukemia |
Procedure: Bone Marrow Aspiration |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia |
Resource links provided by NLM:
Further study details as provided by Stanford University:
Primary Outcome Measures:
- Gene Expression [ Time Frame: days 0, 8, 22 or 29 ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
bone marrow
| Estimated Enrollment: | 120 |
| Study Start Date: | July 2001 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | up to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
All children who present at Packard hospital with a new diagnosis or relapse of acute leukemia will be eligible.
Criteria
Inclusion Criteria:1. All children who present at Packard hospital with a new diagnosis or relapse of acute leukemia will be eligible. There is no bias in regards to age range, gender or ethnic background.
2. Signed informed consent
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01108497
Contacts
| Contact: Norman J Lacayo | (650) 723-5535 | lacayon@stanford.edu |
Locations
| United States, California | |
| Stanford University School of Medicine | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Norman J Lacayo 650-723-5535 lacayon@stanford.edu | |
| Contact: Cancer Clinical Trials Office (650) 498-7061 | |
| Principal Investigator: Norman James Lacayo | |
| Sub-Investigator: Atul J Butte | |
| Sub-Investigator: James M Ford | |
| Sub-Investigator: Hanlee P. Ji | |
| Sub-Investigator: Yasodha Natkunam | |
| Sub-Investigator: Garry Philip Nolan | |
| Sub-Investigator: Maureen M. O'Brien | |
| Sub-Investigator: Joshua D Schiffman | |
| Sub-Investigator: Branimir I Sikic | |
Sponsors and Collaborators
Stanford University
Investigators
| Principal Investigator: | Norman James Lacayo | Stanford University |
More Information
No publications provided
| Responsible Party: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT01108497 History of Changes |
| Other Study ID Numbers: | PEDSHEM0001, 11062, SU-09112009-3881 |
| Study First Received: | April 20, 2010 |
| Last Updated: | December 11, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Leukemia Neoplasms by Histologic Type Neoplasms |
ClinicalTrials.gov processed this record on May 16, 2013